patent.fyi
Applications  /  US 2026/0355510
United States Patent Application Publication

US 2026/0355510 A1

Published
Nov 12, 2026
Filed
May 12, 2026
Earliest date on the face
May 12, 2025
Classification
A61N 1/36002
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.1Block downstream kinase signaling

What ifWhat if the composition contains a selective MEK inhibitor as its sole active ingredient?
Claim language“comprises at least one BRAF inhibitor”

The MEK inhibitor binds MEK1 and MEK2 and reduces phosphorylation of ERK1 and ERK2. In cancer cells that depend on this pathway, reduced ERK activity slows cell-cycle progression and suppresses proliferation.

1.1Stabilize mitotic spindle microtubules

What ifWhat if the composition contains a microtubule-stabilizing taxane as its sole active ingredient?
Claim language“at least one RAS inhibitor”

The taxane binds beta-tubulin in assembled microtubules and suppresses their normal assembly and disassembly dynamics. Disrupted spindle dynamics interfere with chromosome segregation and trigger death in a fraction of dividing cancer cells.

1.1Freeze tissue with a cryoprobe

What ifWhat if a sealed cryoprobe freezes the cancer cells in place?
Claim language“administering at least one composition”

A refrigerant expands inside a closed probe tip and extracts heat through the probe wall. Repeated freezing and thawing cause ice formation and osmotic stress that damage cells in the frozen tissue.

1.2Heat tissue with ultrasound

What ifWhat if a focused ultrasound beam heats the cancer cells?
Claim language“an alternating electric field”

A piezoelectric transducer directs acoustic energy into a focal volume within the tumor. Several seconds of sonication raise the focal tissue temperature above about 60 °C, which denatures proteins and produces coagulative necrosis.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Veterinary tumor organoid drug testing

A veterinary diagnostic laboratory divides organoids from a canine tumor biopsy among matched culture wells. Opposing insulated electrodes on the long sides of each treatment well connect to an alternating voltage generator. The laboratory adds a BRAF inhibitor to the culture medium, energizes the electrodes, and measures organoid viability alongside matched field-only, inhibitor-only, and untreated wells.

Component substitution

Direct current coupling through salt bridges

A culture chamber uses agarose salt bridges in place of dielectric barriers between the electrodes and the culture medium. Each bridge connects one end of the chamber to a separate reservoir containing a platinum mesh electrode. A bipolar constant-current driver supplies alternating current through the bridges, and two voltage probes spaced along the culture chamber measure the field during inhibitor exposure.

Parameter or scale variation

Three electrode pairs for directional cycling

A hexagonal culture chamber carries six insulated electrodes arranged as three opposing pairs with field axes 60 degrees apart. An electronic switch connects one pair at a time to an alternating voltage generator for 2 seconds before advancing to the next pair. The controller cycles through all three directions during a single exposure while the inhibitor remains in the culture medium.

Combination with existing systems

Electric field exposure during continuous perfusion

A perfusion culture cassette holds a tumor slice between porous support membranes and places insulated electrodes on opposite sidewalls. A syringe pump feeds inhibitor-containing medium through the cassette, and an outlet directs spent medium to a collection vial. An alternating voltage generator drives the electrodes across the slice while the pump maintains flow.

Automated or data-driven variant

Feedback control of chamber field strength

Two high-impedance voltage probes sit a known distance apart along the field axis of a culture chamber containing cancer cells and a RAS inhibitor. A controller measures the alternating voltage between the probes and divides its root-mean-square value by the probe spacing to estimate the average field along that segment. The controller adjusts the generator amplitude to maintain the programmed field as the conductivity of the medium changes.

Image-guided exposure of organoid wells

An automated microscope maps organoid positions in a culture plate whose wells have individually switched electrode pairs. Image analysis identifies wells with organoids inside a predefined size range, and a liquid handler dispenses inhibitor-containing medium into those wells. The controller connects the selected electrode pairs to an alternating voltage generator and records the exposure duration for each well.

Specific version of a part

Deliver a focused photon dose

A linear accelerator generates megavoltage photons, and a multileaf collimator shapes each beam to the target projection. Beams delivered from multiple angles deposit absorbed dose in the tumor, producing DNA damage that prevents a fraction of cells from forming viable colonies.

Heat tissue with laser light

A fiber with a diffusing tip delivers light inside the tumor, where tissue absorption converts optical energy to heat. Magnetic resonance thermometry tracks the temperature distribution during delivery, and the heated region undergoes coagulative necrosis when it reaches an ablative thermal dose.

Oral mutant BRAF inhibitor

An immediate-release tablet contains a small molecule that inhibits the kinase activity of BRAF carrying the V600E substitution. The tablet disintegrates in the gastrointestinal tract, and the absorbed inhibitor reaches the tumor through the bloodstream and reduces downstream MEK phosphorylation.

Covalent mutant RAS inhibitor

An oral capsule contains a small molecule that binds the switch II pocket of GDP-bound KRAS carrying the G12C substitution. An electrophilic group forms a covalent bond with cysteine 12 and stabilizes the inactive GDP-bound state.

Two-axis transcutaneous field delivery

Two pairs of skin-mounted arrays contain dielectric-coated ceramic electrodes and conductive hydrogel at the skin interface. A generator supplies a 200 kHz sinusoidal voltage to one pair at a time and switches between the approximately perpendicular field directions every second.

Capacitive field exposure in culture

Two insulated electrodes on opposite walls of a culture chamber capacitively couple a 150 kHz sinusoidal field into the medium. The generator maintains a field of 1.5 V/cm root mean square at the cell layer for 72 hours while the chamber stays at 37 °C.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2015/0133794 A1
Published
May 14, 2015
Filed
Sep 23, 2014
Class
A61B 5/0059
Document BUS 2024/0139192 A1
Published
May 2, 2024
Filed
Dec 8, 2023
Class
A61K 31/517
Claim 1
Document A
Document B
1.1(1) administering at least one composition to the cancer cells, wherein the at least one composition comprises at least one BRAF inhibitor and/or at least one RAS inhibitor; and
Briefly, 8000 cells/well in 12 μl media/well are plated in the 384-well plate and left overnight in the incubator (at 37° C. with 5% CO2-humidified atmosphere), the following day the plate is treated in duplicate with test compounds, dabrafenib and PLX8394 (the latter two as controls) at the following final drug concentrations: 10 μM-3 μM-1 μM-0.3 μM-0.1 μM-0.03 μM-0,01 μM-0.003 μM-0.001 μM, all wells are subjected to DMSO normalization and drug incubation occurs for 1 hour.
B · US 2024/0139192 A1 · ¶ 39
1.2(2) applying an alternating electric field to the cancer cells for a period of time.
In the case of circulating cancer cells, the present invention provides a method for their non-invasive indication by the response of biological cells to the application of an oscillating electric field gradient on a specified area of the human body.
A · US 2015/0133794 A1 · ¶ 63

An empty cell means only that no passage was reproduced there.

Statements in these documents
The present invention relates to measuring a medical parameter and more particularly to a cancer cell detection device.
A · US 2015/0133794 A1 · ¶ 2
That patent was not concerned with cancer cells per se; however, the techniques taught in that patent can be used with embodiments and devices of the present invention to detect and monitor cancer cells both in-vitro, in-vivo, and non-invasively.
A · US 2015/0133794 A1 · ¶ 4
The present invention provides in particular a BRAF inhibitor and a MEK inhibitor for use in the treatment of cancer, wherein the BRAF inhibitor is a compound of formula (I):
B · US 2024/0139192 A1 · ¶ 3
However, rapid acquisition of drug resistance is almost universally observed and the duration of the therapeutic benefits for the targeted therapy remains limited.
B · US 2024/0139192 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0355510 A1, claim 1, first published 2026-11-19T12:21:55-05:00, https://patent.fyi/US20260355510/, SHA-256 ee61ce2ff016bf1417caba80ef3bdeefc6b4334992bf461bff068e4c7f7d73fe
First published
Permanent addresshttps://patent.fyi/US20260355510/
Content fingerprint (SHA-256)ee61ce2ff016bf1417caba80ef3bdeefc6b4334992bf461bff068e4c7f7d73fe
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi